Principal Investigator Stefan Kappe and his lab lead a GAP3KO trial for a potential malaria vaccine candidate. If the trial is succesful, it may lead to a fundamentally different type of malaria vaccine. >>More

While at Seattle BioMed, Dr. Leo Stamatatos and his research team discovered an HIV vaccine candidate that stimulates the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains. >>More

Seattle BioMed President and Director Alan Aderem has written an op-ed for the Seattle Times about the critical importance of NIH funding in developing infectious disease research . Join us in seeking congressional action.   >>Learn More

Professor John Aitchison is a co-recipient of a $10.9 million grant from the NIH’s Institute of General Medical Sciences to establish a new Biotechnology Resource to aid researchers in interpreting complex biological systems, such as cancer and infectious diseases.   >> More

Novel Agents Capable of Killing TB Identified

Researchers in the lab of Professor David Sherman, Ph.D., have developed and screened several compounds with antibacterial properties capable of destroying Mycobacterium tuberculosis (Mtb), the bacterium that causes TB. These compounds, called anti-folates, block the folate pathway, which is responsible for the synthesis of the essential cellular building blocks, without which Mtb cannot survive. The results of this study were published in the June issue of the journal Chemistry and Biology.  More >>

Collaboration and Systems Biology Needed for Scientific Discovery

In December's issue of Infecious Disease News, Scientific Director John Aitchison, PhD and CFO Louis Coffman discuss the importance of a systems biology approach to infectious disease research. This comprehensive study of interactions coupled with frequent collaboration is key in the discovery and development of lifesaving vaccines and drugs. >>More

News + Events

February 2, 2015

Connect with Us

Stay informed. Sign up for our email newsletter